GlobeNewswire

Partners Justin Watts and Matthew Shade Bolster WilmerHale's IP Litigation Practice in London

Dela

LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- WilmerHale today announced that Justin Watts, PhD, and Matthew Shade, PhD, have joined the firm as partners in its London office, strengthening WilmerHale's position as a firm of choice for complex patent litigation in the United Kingdom and for clients seeking an effective global strategy for their intellectual property disputes.

Dr. Watts, a first-chair patent litigator with deep experience in international disputes including competition matters, and Dr. Shade, a skilled practitioner and former patent examiner in the European Patent Office, come to WilmerHale from a Magic Circle firm, where Dr. Watts was the head of the firm's UK IP litigation practice. Together they bring more than 30 years of combined practice, with experience in a wide range of technologies, including cell phones, pharmaceutical products, semiconductors and aero engines."

"Justin and Matthew are an impressive duo who will substantially strengthen our international patent litigation capabilities," said Susan Murley, co-managing partner of WilmerHale. "Their experience with high-stakes IP litigation work and ability to manage complex international patent disputes will benefit our life sciences and tech clients alike."

"The opportunity to join WilmerHale allows us to be a part of a firm that boasts the most esteemed IP litigation practice in the United States," said Dr. Watts. "Matthew and I are looking forward to joining the WilmerHale team and contributing our UK and EU expertise to extend the ways in which clients can rely upon WilmerHale for well-coordinated and comprehensive guidance in global patent litigation matters."

WilmerHale's IP Litigation Practice features a premier litigation team backed by the academic and industry experience of more than 100 lawyers and technology specialists with scientific or technical degrees. WilmerHale's lawyers have tried major cases in US federal district courts from coast to coast, before the US International Trade Commission, and in Germany and the United Kingdom. The firm's lawyers also regularly represent clients in patent appeals before the US Supreme Court and the Federal Circuit. Since the first year the title of IP Litigation Department of the Year was awarded in 2004, The American Lawyer has honored WilmerHale twice and a finalist six times in this biennial contest. 

Mark Selwyn, co-chair of WilmerHale's IP Litigation Practice, added, "It is with great pride that we welcome Justin and Matthew. They bring a superb track record of success and commitment to legal excellence, and they will further enhance our ability to offer clients the finest representation for their global IP litigation disputes." 

Biographical Information

Dr. Justin Watts

Justin Watts, a patent litigator, was most recently a partner in the IP and information technology practices of a Magic Circle firm, where he was the head of the firm's UK IP litigation practice. Dr. Watts has handled complex, multinational disputes, often involving the intersection of antitrust and intellectual property. He has appeared before UK courts and high courts of Northern Ireland and Singapore, and has coordinated international patent litigation in the US, Germany and the Netherlands. His clients span a range of industries from pharmaceutical and medical device to technology, media and communications.

Dr. Watts is a highly regarded practitioner, earning consistent recognition by industry publications such as Chambers UK and The Legal 500 UK, by which he has been cited as "one of the best and most strategic litigators in the field."

Before his legal career began in 1994, Dr. Watts worked in satellite communications engineering. He earned his BA in electrical sciences and his PhD in optoelectronics from the University of Cambridge, and his diploma in IP law and practice, with commendation, from the University of Bristol.

Dr. Matthew Shade

Matthew Shade was most recently a patent litigator at a Magic Circle firm, where he was a member of the firm's intellectual property and information technology practices since 2007. His work focuses on complex multijurisdictional patent cases, and he often deals with the interface of intellectual property and antitrust law. Dr. Shade has practiced before the English courts and the European Patent Office. His clients span industries from pharmaceuticals and medical devices to consumer electronics.

Previously, Dr. Shade managed the patent department of a high-tech spin-out from Cambridge University and he was a patent examiner at the European Patent Office. He earned his BS, with honors, from the University of Manchester, and his PhD in chemistry from the University of Oxford. He is a registered solicitor in England and Wales and a European patent attorney.

About Wilmer Cutler Pickering Hale and Dorr LLP

WilmerHale provides legal representation across a comprehensive range of practice areas that are critical to the success of its clients. The law firm's leading Intellectual Property, Litigation/Controversy, Regulatory and Government Affairs, Securities and Transactional Departments participate in some of the highest-profile legal and policy matters. With a staunch commitment to public service, the firm is renowned as a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia. For more information, please visit www.wilmerhale.com.

Lauren C. Bishop
WilmerHale
lauren.bishop@wilmerhale.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WilmerHale via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum